

Progress beyond progression: A new treatment option for advanced RCC in 2016

Monday 10 October 13:00 - 14:30

Berlin Auditorium, Bella Center
Copenhagen, Denmark

Chair's Welcome

Dear Colleague,

On behalf of the faculty, it gives me great pleasure to invite you to the IPSEN satellite symposium 'Progress beyond progression: A new treatment option for advanced RCC in 2016' to be held during the ESMO 2016 Congress.

During this symposium, we will provide an update regarding the biology of advanced RCC and provide an overview of the research programme for cabozantinib in this setting. We will also look at the implications of recent trial findings for RCC treatment guidelines, and discuss important considerations relating to clinical treatment decision making in the context of RCC disease progression.

I look forward to welcoming you to Copenhagen and I hope you will join us for what promises to be an engaging and highly educational symposium.



Professor Bernard Escudier
Institut Gustave Roussy, France

Agenda

Time	Title and Topic	Presenter
13:00 - 13:10	Welcome and introduction	Bernard Escudier
13:10 - 13:30	Biology of advanced RCC: Beyond VEGF and mTOR	Eric Jonasch
13:30 - 13:50	Cabozantinib: A novel agent for the second-line treatment of advanced RCC	Toni Choueiri
13:50 - 14:10	How will new evidence inform treatment guidelines and clinical decision making in RCC?	Cora Sternberg
14:10 - 14:30	Panel discussion and final remarks	All